Zelminemab is a humanized monoclonal antibody that inhibits the pituitary adenylate cyclase-activating polypeptide type 1 (PAC1) receptor; it is used for research purposes to study PAC1 receptor-mediated signaling pathways and related physiological or pathological processes.